Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies
Immunotherapy is a promising strategy for the treatment of Alzheimer’s disease (AD). Antibodies directed against Amyloid Beta (Aβ) are able to successfully clear plaques and reverse cognitive deficits in mouse models. Excitement towards this approach has been tempered by high profile failures in the clinic, one key issue has been the development of inflammatory side effects in the brain (ARIAs). New antibodies are entering the clinic for Alzheimer’s disease; therefore, it is important to learn all we can from the current generation. In this study, we directly compared 3 clinical candidates in the same pre-clinical model, with the same effector function, for their ability to clear plaques and induce inflammation in the brain. We produced murine versions of the antibodies: Bapineuzumab (3D6), Crenezumab (mC2) and Gantenerumab (chGantenerumab) with an IgG2a constant region. 18-month transgenic APP mice (Tg2576) were injected bilaterally into the hippocampus with 2 µg of each antibody or control. After 7 days, the mice tissue was analysed for clearance of plaques and neuroinflammation by histology and biochemical analysis. 3D6 was the best binder to plaques and in vitro, whilst mC2 bound the least strongly. This translated into 3D6 effectively clearing plaques and reducing the levels of insoluble Aβ, whilst chGantenerumab and mC2 did not. 3D6 caused a significant increase in the levels of pro-inflammatory cytokines IL-1β and TNFα, and an associated increase in microglial expression of CD11B and CD68. chGantenerumab increased pro-inflammatory cytokines and microglial activation, but minimal changes in CD68, as an indicator of phagocytosis. Injection of mC2 did not cause any significant inflammatory changes. Our results demonstrate that the ability of an antibody to clear plaques and induce inflammation is dependent on the epitope and affinity of the antibody.
KeywordsImmunotherapy Alzheimer’s disease Bapineuzumab Gantenerumab Crenezumab Inflammation
One neuropathological hallmark of Alzheimer’s disease (AD) is the accumulation of amyloid β (Aβ) as extra-cellular deposits. Data from both familial and sporadic forms of AD led to the hypothesis that Aβ is central to the pathogenesis of AD . As a result there has been a great effort to develop drugs that will reduce the production of Aβ or clear the deposits. One approach has been to immunise against Aβ, either by active immunisation against Aβ or by passive immunisation with anti-Aβ antibodies. Active immunisation of transgenic APP mice with Aβ clears plaques and reverses memory deficits , but active immunotherapy in AD patients is associated with severe inflammatory side effects . Passive immunotherapy with monoclonal anti-Aβ antibodies also reduces amyloid deposition and reverses cognitive deficiencies in transgenic APP mice [2, 9, 32]. Due to this success in experimental models, several monoclonal antibodies reached clinical trials for the treatment of AD, but excitement towards this approach has been tempered by a number of high profile failures to deliver disease-modifying effects. Bapineuzumab and Solanezumab both failed in phase III, and a phase III trial for Gantenerumab was abandoned after a futility analysis [12, 23]. With more antibodies for AD entering the clinic, including Aducanumab, which has shown promising effects in Phase I, it is imperative to learn from the first-generation antibody therapies to inform the development of new and improved clinical candidates. Bapineuzumab, a humanised IgG1, which recognised the N terminus of Aβ cleared plaques from the brains of patients in a phase II trial, however, it also caused oedema and micro-haemorrhage of the cerebral vasculature [22, 24]. These side effects limited the top dose in phase III trials, which potentially contributed to the lack of efficacy . These side effects have also been observed with Gantenerumab (hIgG1, N terminus conformational epitope). Pre-clinical studies have suggested that side effects could be due to inflammation caused by Fc effector function of the therapeutic antibodies, as de-glycosylation can prevent vascular damage in vivo [6, 13, 29]. With this in mind, Crenezumab (hIgG4, mid-domain epitope) was generated with a human IgG4 constant region to modify Fc effector function and reduce vascular side effects .
The efficacy to clear plaques and the potential to induce side effects is difficult to predict due to inconsistent use of experimental models, epitope specificity of the antibody tested (N, mid or C terminus) or antibody subclass. In this study, we set out to compare three antibodies which have been in phase III clinical trials for AD: Crenezumab, Bapineuzumab and Gantenerumab. Bapineuzumab is a human IgG1 antibody, which binds to the N terminus of Aβ (AA 1–5), and can recognise both soluble and insoluble Aβ . Gantenerumab is also a human IgG1 antibody which recognises a conformational epitope, making contact with the n terminus and the mid-domain of Aβ, reportedly binding more strongly to more aggregated forms compared to soluble Aβ . Crenezumab is a human IgG4 antibody which recognises a mid-domain epitope (AA 16-24), and binds to all forms of Aβ . We produced murine versions of Crenezumab (mC2), Bapineuzumab (3D6) and a mouse/human chimeric version of Gantenerumab (chGantenerumab) all with an IgG2a constant regions. We compared these antibodies for their ability to clear Aβ plaques and to induce neuroinflammation following intracerebral injection into transgenic APP mice (Tg2576). Murine IgG2a subclass was selected as this subclass is similar to hIgG1 in terms of FcγR binding, and hIgG1 has been the most commonly used subclass for anti-Aβ immunotherapy. Here, we show that the affinity and epitope specificity are important for the efficient removal of Aβ from the CNS, but also for the induction of a neuroinflammatory response.
Recombinant antibody production
Sequences of antibodies used in study
Heavy chain variable domain sequence
Light chain variable domain sequence
US Patent No. 7,790,856B2
EMBL database ID: CHEMBL1743025
WO 2008011348 A2
WO 2007068412 A2
Mouse IgG2A Constant domain
Mouse Kappa chain constant domain
Abeta binding assay
Binding characteristics of the recombinant antibodies to Aβ peptide was assessed as follows: 96-well Maxisorp plates (Nunc, Denmark) were coated with 100 µl of 0.1 µg/ml Aβ 1–40 peptide (America Peptide, Sunnyvale, CA) in bicarbonate buffer (pH 9.6) overnight at room temperature. Plates were washed 5 times with PBS/0.1 % Tween and recombinant anti-Aβ antibodies were serially diluted in 100 µl of assay buffer (PBS/1 % BSA) and incubated for 1 h at room temperature. After washing plates 5 times with PBS/0.1 % tween, antibody binding was detected by the addition of 100 µl of using horse anti-mouse IgG conjugated to biotin (vector) diluted 1:200 in assay buffer. Plates were washed 5 times before addition of 100 µl streptavidin poly-HRP (1:10,000 in assay buffer, Sanquin, the Netherlands). Bound antibody was detected using tetramethylbenzidine (TMB) (Sigma) as a substrate. The substrate solution was made by dissolving 1 TMB tablet in 1 ml of DMSO, which was made up to 10 ml in phospho-citrate buffer (Sigma), 2 µl of 30 % H2O2 (Sigma) was added to the solution directly before addition to the plate. 100 µl of the substrate solution was added to each well and allowed to develop. The reaction was stopped by the addition of 50 µl H2SO4 to each well, and absorbance was measured at 450 nm using a Fluostar Optima™ spectrophotometer.
Cell culture and effector function assay
The mouse macrophage cell line RAW 264.7 was cultured in DMEM media (Gibco) supplemented with 10 % heat inactivated foetal calf serum (FCS, Sigma) and 2 mM glutamine (Sigma). Cells were incubated at 37 °C with 5 % CO2. Effector function of the recombinant antibodies was measured in vitro by immobilising antibodies (100 µl/well, 5 µg/ml antibody in pH 9.6 bicarbonate buffer) to U.V. sterilised 96 well ELISA plates (Nunc, Maxisorp Flat bottom). Unbound antibodies were removed by washing the plates with DMEM, plates were then blocked with cell culture medium containing 10 % FCS for 1 h, then 4 × 104 RAW cells per well were added in DMEM media containing 100 units per ml of murine IFN-γ (Peprotech). The cells were cultured for 24 h and supernatant removed to measure the levels of TNFα by ELISA.
TNFα levels were measured in cell culture supernatant using TNFα duoset™ ELISA (RnD systems), according the manufacturer’s instructions, with minor modification. Briefly, capture antibodies were coated onto maxisorp plates in 100 µl 0.1 M bicarbonate buffer pH 9.4 overnight at room temperature. The plates were washed 5 times in PBS 0.05 % Tween. Cell culture supernatant or TNFα standard serially diluted in assay buffer (PBS/1 % BSA) was added and plates incubated for 2 h on a shaking table. After washing the plates, the secondary biotinylated antibody was added incubated for a further 2 h, before the addition of poly-HRP (1:10000 in PBS/1 %BSA, Sanquin, the Netherlands). This assay was developed and measured in the same way as the Aβ binding ELISA.
Animals and stereotaxic surgery
Female Tg2576 transgenic mice possessing a copy of human APP with the Swedish double mutate on (KM670/671NL) were obtained from Taconic and aged to 18 months. Mice were kept in 12 h light–dark cycles with free access to food and water. Mice were randomised into 4 groups (3D6, mC2, Gantenerumab or irrelevant mIgG2a control (n = 6/7 per treatment group). Mice were weighed and anaesthetised using sevoflurane, and secured onto a stereotaxic frame. A mid-sagittal incision was made exposing the skull, and two burr holes were made at coordinates (−2.0, +1.7) and (−2.0, −1.7). A fire pulled glass capillary with a diameter of <50 μm (Sigma) was inserted −1.4 mm into the brain and 2µl of antibody (1 mg/ml) was slowly injected bilaterally. This method allows accurate injection of 2 µg of mAb with minimal mechanical damage. Sutures were used to close scalp and mice were left to recover in a thermo-regulated environment. All procedures were carried out in accordance with Danish law.
Seven days after the injections the mice were terminally anaesthetised using avertin, and transcardially perfused with heparinised saline. The brain was removed and cut to two hemispheres. The left hemisphere was further dissected, and a hippocampal punch was taken as described before  and frozen in isopentane over dry ice. The right hemisphere was mounted in optimal cutting temperature medium (OCT, Sakura Finetek, Thatcham, UK) for immunohistochemistry.
Brains were cut into 10 micron sections using a cryostat. A series of sections through the hippocampus was taken, and the site of injection was located by staining for CD11B; this allowed identification of the antibody-injected brain region to use for further immunohistochemistry. Immunohistochemistry was performed as described before  using CD11B (5C6, 1:500, Serotec), CD68 (FA11, 1:500, Serotec) and Aβ (3D6, 1:1000, in house), FITC sheep anti-mouse F(ab)2 (1:500, Sigma), horse anti-mouse biotinylated (1:250, Vector) and rabbit anti rat biotinylated (1:250, Vector).
Congo red staining
Ten micron sections were dried at 37 °C for 30 min, and fixed in 4 °C ethanol for 15 min before washing in three changes of PBS. Sections were stained for 15 min in 0.3 % Congo red (Sigma) in 80 % ethanol containing 0.01 % NaOH (Sigma). Sections were de-stained by dipping five times in 50 % ethanol containing 0.02 % NaOH, and transferred into PBS. Slides were mounted using Pro-long gold™ anti-fade reagent (Invitrogen) containing the counterstain DAPI.
Aβ staining in human tissue
The postmortem tissue of the AD cases was provided by BRAIN UK under the ethics approval obtained from the National Research Ethics Committee South Central Hampshire B (REC reference 14/SC/0098). Formalin-fixed paraffin-embedded brain tissue was cut into 5 µm sections on a microtome. Tissue was dewaxed in clearene (Surgipath), and rehydrated in graded alcohols. Endogenous peroxidase activity was quenched by incubation of tissue with 3 % H2O2 in methanol for 10 min, before 3 washes with tris-buffered saline (TBS). Sections were then either incubated for 30 min in 80 % formic acid (Fisher) or in TBS. Sections were blocked for 30 min with medium containing DMEM, FCS BSA. Anti-Aβ antibodies were added at a concentration of 1:1000 in TBS and incubated at 4 °C overnight. Sections were then washed in 3 rinses of TBS before addition of biotinylated rabbit anti-mouse IgG secondary (Abcam, 1:600) and incubated for 1 h. Bound antibody was detected by incubation for 30 min with ABC system (Vector), and washed 3 times in TBS, before developing with diaminobenzidine solution (DAB, Vector). Slides were dehydrated in graded alcohols into clearene, before mounting with pertex™ (Cellpath).
Quantification of immunohistochemistry
Light microscopy (DAB) and fluorescent images were taken on a Leica DM5000 microscope using QWIN or LAS software. The quantification of DAB images was performed using the freeware—ImageJ. Images taken with a 20× objective were de-convoluted using HDAB RGB values, which split images into haematoxylin and DAB channels. The DAB staining was turned into a binary image, and the percentage area above a marker-specific threshold was measured. To quantify congophilic plaques, the number of Congo red-positive deposits was counted in the hippocampus. The number of plaques was then normalised to hippocampal area. During all quantification, the slides were blinded to prevent bias.
MSD measurement of Aβ and cytokines
Protein was extracted from hippocampal punches in 2 stages, as described previously . First, hippocampal tissue was placed in a buffer containing: 150 mM NaCL, 25 mM TRIS 1 % triton x-100 and complete mini protease inhibitors (Roche). The tissue was mechanically homogenised and the homogenate was centrifuged at 20,000g at 4 °C for 1 h to remove insoluble material. The supernatant from this fraction was used to measure pro-inflammatory cytokine levels and the triton soluble Aβ fraction using multiplex MSD technology. The pellet was re-suspended in 70 % formic acid and incubated for 15 min to solubilise aggregated forms of Aβ, this solution was neutralised in 20 volumes of pH8 TRIS, and centrifuged at 20,000g for 1 h and the supernatant used to measure the formic acid soluble Aβ fraction. Total protein levels were measured by BCA protein assay (Pierce), and final levels were expressed as pg/mg protein. The multiplex Aβ assay c-terminal antibodies to capture specific Aβ peptides, and uses the antibody 6E10 (AA 1-16) for detection.
All data are expressed as mean ± standard deviation. Statistical analysis was performed and figures created using Graphpad Prism software. Data were first analysed for normal distribution; normally distributed data were analysed by one-way ANOVA and then treatment groups were compared using TUKEY post hoc analysis. Non-parametric data were analysed using non-parametric equivalents.
Three murine anti-Aβ antibodies: 3D6, mC2 and chGantenerumab were generated recombinantly from the variable domain amino acid sequences. All antibodies were produced with the same mouse IgG2a constant regions, to ensure they had the same effector function. The antibodies were purified and free from endotoxin and IgG aggregates prior to use in experiments. 3D6 and mC2 were the original parent antibodies of Bapineuzumab and Crenezumab.
Clearance of Aβ
There have been a number of high profile clinical disappointments for anti-Aβ immunotherapy, with Bapineuzumab, Solanezumab, Crenezumab and Gantenerumab all failing to show disease-modifying effects in clinical trials. Differences in: epitope and affinities for Aβ, FcγR affinity and the pre-clinical models used for characterisation make direct comparison difficult. Therefore, to better understand the underlying biological mechanisms, we compared three highly characterised clinical candidates, Bapineuzumab, Gantenerumab and Crenezumab for their ability to clear plaques and induce neuroinflammation in an experimental model of Alzheimer’s disease (Tg2576). We generated murine, recombinant versions of Bapineuzumab (3D6), Crenezumab (mC2) and a mouse/human chimeric version of Gantenerumab (chGantenerumab). These antibodies were produced using the same murine IgG2a constant regions, and were injected intracranially into 18-month Tg2576 mice. The murine IgG2a constant region is most similar to human IgG1 and has a strong ability to activate human FcγRs and induce inflammation . We are not aware of previous studies that directly compare murinised versions of Bapineuzumab, Crenezumab and Gantenerumab for their ability to clear plaques and induce inflammation.
We show that all IgG2a antibodies bind to recombinant immobilised peptide and plaques present in the Tg2576 brain tissue sections, with 3D6 displaying the highest relative affinity to Aβ. The antibody chGantenerumab also bound with high affinity to immobilised Aβ peptide, but showed strong binding to neurons in cryosections of both transgenic and wild-type animals. mC2 was able to bind Aβ peptide in vitro and plaques in vivo, but the relative affinity was 100-fold weaker than for 3D6. These observations are relevant for biological function, as 3D6, which had the strongest affinity for Aβ plaques in our model, was the only antibody to significantly reduce Aβ levels in vivo. Due to the potential of antigenic masking to affect the results from immunohistochemistry and MSD assay, we used Congo red staining and demonstrate that plaque numbers are reduced following 3D6 treatment. 3D6 injection also induced the activation of microglia as measured by their increase in CD11B expression and increased levels of the pro-inflammatory cytokines, IL-1β and TNFα. One of the mechanisms of antibody mediated plaque clearance is through activation of microglia FcγRs and phagocytosis [30, 31]. Crosslinking of FcγRs by immune complexes leads to switching to an “M2b” phenotype , characterised by the production of reactive oxygen species and pro-inflammatory cytokines, including IL-1β and TNFα. The antibody subclass we used for this experiment, mouse IgG2a, is a potent inducer of inflammation due to its high affinity for activating receptors . It has previously been shown that the IgG2a version of the anti-pyroglutamate mE8 is better at clearing plaques than the IgG1 version (with lower FcγR affinity), implying that FcγRs are involved in the clearance of plaques . Gantenerumab did not significantly reduce the levels of Aβ, but detection of mouse IgG bound to plaques provides clear evidence for target engagement. Like 3D6, increased expression of CD11B was observed but minimal change in CD68 expression levels suggest less efficient phagocytosis following injection of chGantenerumab. As all antibodies were generated as IgG2a isotypes, this lack of phagocytosis and plaque clearance is not due to lack of effector function, but rather dependent on the affinity and/or epitope. Bapineuzumab and Gantenerumab bind to residues in the N terminus of Aβ, crystal structures of Bapineuzumab in complex with Aβ show that it binds to amino acids 1–5 which are in helical conformation . Gantenerumab, in contrast, binds to a conformational epitope which also includes residues in the mid-domain . chGantenerumab has a lower EC50 in our Aβ1-40 binding ELISA, when compared to murine 3D6 (0.34 vs 0.17 pM, respectively) and therefore, clearance of plaques may require more time—this is supported by the changes in microglial phenotype and cytokine production. The antibody mC2 was unable to clear Aβ plaques 7 days post-injection, but unlike chGantenerumab, this antibody did not induce any detectable changes in microglial phenotype or cytokine levels, despite having similar effector function. Immunoreactivity for mouse IgG strongly implies that the lack of clearance is due to poor plaque engagement, as IgG levels were not different from control IgG2a antibody. mC2 binds to a mid-domain epitope (AA 16–24) and studies of other antibodies that bind this region such as, m266 (Solanezumab), suggest that this epitope is inaccessible when Aβ is in aggregated forms and this prevents antibodies like m266 from binding to and clearing plaques . This is supported by binding to formic acid-treated sections, which shows that mC2 requires the solubilisation of plaques with formic acid to bind. Our results demonstrate that targeting the N terminus of Aβ is more effective for plaque clearance. The ability of Crenezumab and Solanezumab to engage human Aβ in AD cases has previously been questioned, and cross-reactivity for a number of antigens has been reported . We, however, found that mC2 was able to bind to Aβ in immunohistochemistry of human AD tissue. Antibodies that are unable to bind to Aβ plaque without formic acid antigen retrieval may not be able to engage plaques in the brains of AD patients. The inability to engage plaques strongly may prevent the removal of aggregated Aβ species from the brain following immunotherapy.
AD patients treated with Bapineuzumab or Gantenerumab have developed dose-limiting vascular side effects (ARIAs), but the underlying mechanisms are not completely understood. There is evidence that activation of microglia, and/or perivascular macrophages through FcγRs and the subsequent neuroinflammation may be partly responsible for these side effects. It has been shown that reduced binding to FcγR can decrease the incidence of vascular damage in mice [6, 13, 29]. In this study, we provide further experimental evidence that antibody engagement with activating FcγRs generates a pro-inflammatory response in the brain, as IgG2a versions of 3D6 and chGantenerumab both resulted in microglial activation and elevated cytokine production. The clinical candidate Crenezumab is built on a hIgG4 backbone, which has significantly reduced FcγR affinity compared to hIgG1. This was aimed to reduce the inflammatory response to immunotherapy and therefore reduce the associated side effects, and indeed ARIAs were not reported in patients treated with 10x the maximal dose of Bapineuzumab . Our study provides an alternative explanation for the lack of side effects: the lack of plaque engagement by the antibody. We show that intracranial injection of an IgG2a murine version of Crenezumab-mC2 failed to clear plaques or induce a pro-inflammatory response. These observations suggest that inflammation related to immunotherapy is not just dependant on the ability of the antibody to engage FcγRs but also on the epitope and ability of the antibody to engage plaques.
3D6 and mC2 are not exactly the same as the final clinical candidates; Bapineuzumab and Crenezumab. This could mean there are slight differences in the binding affinity which could influence the rate of Aβ clearance and inflammation; therefore, extrapolating these data should be done with caution. However, the clinical antibodies share the same epitope and are incredibly similar in sequence, and therefore the response is likely to be similar. Intra-cranial injection is a useful technique allowing rapid and cost-efficient characterisation of the response to an antibody, however, there are some limitations to this approach. To limit injection-mediated tissue damage, we use fine pulled glass capillaries to inject into the brain. However, even with caution any injection will cause some tissue damage, which may influence the subsequent immune response. Patients are not injected intracranially with these antibodies, and therefore, injecting directly into the brain is less relevant to the clinic than giving a systemic dose of the antibodies. One factor to consider is that the localised concentration of IgG following central injection will be higher than after systemic treatment, which could therefore influence the neuroinflammatory response. To fully characterise the differences between these antibodies, a systemic trial is needed which would also allow the measurement of cognitive changes. Previous studies have shown that there is variability in the response between different transgenic APP mouse models, in particular extensively aged mice, after treatment with anti-Aβ antibodies [10, 33]. Therefore, further studies would be required to confirm the findings presented in this manuscript in different models. Furthermore, studies in transgenic APP mice have not always translated into successful clinical trials in humans; therefore, the response to the different anti-Aβ antibodies may differ in human AD patients.
We believe the results presented in the current manuscript can inform the development of optimised clinical antibodies. Treatment with 3D6 is effective at clearing plaques, however, part of this response causes increased neuroinflammation. Optimised immunotherapy for AD ideally separates phagocytosis and neuroinflammation, which would allow clearance of Aβ without the induction of detrimental pro-inflammatory cytokine release. To achieve this, better understanding of the receptors involved in this processes is essential. We know that a range of different FcγRs is expressed in the brains of AD patients and mouse models [8, 14, 21], but the physiological role of these receptors in the brain and their relative contribution to neuroinflammation and plaque clearance remain poorly understood. 3D6 has strong target binding and a high risk of causing vascular side effects and inflammation, therefore, to minimise toxicity reduction of its effector function will likely be beneficial. In contrast, mC2 with lower target binding might need stronger FcγR binding to increase efficacy. Based on our results, we conclude that reduction of the effector function of Crenezumab did not have the expected beneficial effects, and the lack of clinical efficacy may be due to its lower plaque engagement. It is clear that we do not fully understand the role that FcγRs play in the CNS (see recent review , as there is mounting evidence that these receptors play a specific role in the pathology of dementia. In humans, six FcγRs have been identified (activatory receptors, FcγRI, IIa, IIc, IIIa, an inhibitory receptor FcγRIIb and a GPI-linked decoy FcγRIIIb) and the ratio of activatory: inhibitory expression determines the activation threshold of effector cells . Different receptors may play different roles in the clearance of Aβ or in the induction of side effects. Effector function of antibodies is critical to cancer immunotherapy, and much progress has been made in antibody engineering to develop therapeutic antibodies with improved binding to a particular receptor . Better understanding of the role of specific FcγRs in immunotherapy may facilitate the modification of anti-Aβ immunotherapies by antibody engineering to maximise plaque clearance and reduce side effects.
We thank the medical research council (UK) for funding for James Fuller’s studentship, and Lundbeck A/S for extra funding for animals and reagents. We also thank Susanne Lüder for her help in antibody production and: Kasper Larsen, Kate Pedersen and Dr. Anna Parachikova for help with the Tg2576 colony and stereotaxic surgery. Thank you to Dr. Delphine Boche and Dr Sonja Rakic for advice and help with regards to human immunohistochemistry, and Brain UK for AD brain tissue.
- 1.Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK et al (2012) An effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci 32:9677–9689. doi:10.1523/jneurosci.4742-11.2012 CrossRefPubMedGoogle Scholar
- 2.Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang JP, Johnson-Wood K et al (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916–919. doi:10.1038/78682 CrossRefPubMedGoogle Scholar
- 3.Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF et al (2012) Gantenerumab: a novel human anti-A beta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis 28:49–69. doi:10.3233/jad-2011-110977 PubMedGoogle Scholar
- 6.Carty NC, Wilcock DM, Rosenthal A, Grimm J, Pons J, Ronan V, Gottschall PE, Gordon MN, Morgan D (2006) Intracranial administration of deglycosylated C-terminal-specific anti-Abeta antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. J Neuroinflamm 3:11. doi:10.1186/1742-2094-3-11 CrossRefGoogle Scholar
- 8.Cribbs DH, Berchtold NC, Perreau V, Coleman PD, Rogers J, Tenner AJ, Cotman CW (2012) Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J Neuroinflamm 9:179. doi:10.1186/1742-2094-9-179 CrossRefGoogle Scholar
- 9.DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer’s disease. P Natl Acad Sci USA 98:8850–8855. doi:10.1073/pnas.151261398 CrossRefGoogle Scholar
- 10.DeMattos Ronald B, Lu J, Tang Y, Racke Margaret M, DeLong Cindy A, Tzaferis John A, Hole Justin T, Forster Beth M, McDonnell Peter C, Liu F et al (2012) A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer’s disease mice. Neuron 76:908–920. doi:10.1016/j.neuron.2012.10.029 CrossRefPubMedGoogle Scholar
- 22.Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA et al (2010) (11)C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9:363–372. doi:10.1016/s1474-4422(10)70043-0 CrossRefPubMedGoogle Scholar
- 26.Sudduth TL, Greenstein A, Wilcock DM (2013) Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers A beta in APP/PS1 mice along a different time course than anti-A beta antibodies. J Neurosci 33:9684–9692. doi:10.1523/jneurosci.1220-13.2013 PubMedCentralCrossRefPubMedGoogle Scholar
- 29.Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN, Morgan D (2006) Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J Neurosci Off J Soc Neurosci 26:5340–5346. doi:10.1523/JNEUROSCI.0695-06.2006 CrossRefGoogle Scholar
- 30.Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D (2003) Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci Off J Soc Neurosci 23:3745–3751Google Scholar
- 32.Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, Wilson N, Freeman MJ, Gordon MN et al (2004) Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci Off J Soc Neurosci 24:6144–6151. doi:10.1523/JNEUROSCI.1090-04.2004 CrossRefGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.